tradingkey.logo
tradingkey.logo
検索

ANI Pharmaceuticals Inc

ANIP
ウォッチリストに追加
83.050USD
+0.270+0.33%
終値 07/01, 16:00ET15分遅れの株価
1.89B時価総額
20.19直近12ヶ月PER

詳細情報 ANI Pharmaceuticals Inc 企業名

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

ANI Pharmaceuticals Incの企業情報

企業コードANIP
会社名ANI Pharmaceuticals Inc
上場日May 04, 2000
最高経営責任者「CEO」Lalwani (Nikhil Suresh)
従業員数897
証券種類Ordinary Share
決算期末May 04
本社所在地210 Main Street West
都市BAUDETTE
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号56623
電話番号12186343500
ウェブサイトhttps://www.anipharmaceuticals.com/
企業コードANIP
上場日May 04, 2000
最高経営責任者「CEO」Lalwani (Nikhil Suresh)

ANI Pharmaceuticals Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.27K
-23.38%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
58.41K
-4.75%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
38.88K
-5.14%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
38.43K
-36.36%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
37.39K
-1.23%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
29.51K
+14.76%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
11.22K
+38.83%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.27K
-23.38%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
58.41K
-4.75%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
38.88K
-5.14%

よくある質問

ANI Pharmaceuticals Incの上位5名の株主は誰ですか?

ANI Pharmaceuticals Incの上位5名の株主は以下のとおりです。Mr. Chad Gassert

ANI Pharmaceuticals Inc(ANIP)の株式を保有している機関の数はいくつですか?

2026Q1時点で、ANI Pharmaceuticals Incの株式を保有している機関は555社あり、保有株式の総市場価値は約23.15Mで、全体の101.74%を占めています。2025Q4と比較して、機関の持ち株は57726.00増加しています。

ANI Pharmaceuticals Incの最大の収益源は何ですか?

2026Q1において、Sales of generic pharmaceutical products部門がANI Pharmaceuticals Incにとって最大の収益を生み出しており、その金額は384.11Mで、全収益の43.48%を占めています。